Is There a Real GLP-1 Coupon? Savings Cards, PAPs & Free Samples in 2026

Is there really a GLP-1 coupon — or is it always a brand thing?

"GLP-1 coupon" gets searched as if it were one program, but there's no category-wide discount that applies across Ozempic, Wegovy, Mounjaro, and Zepbound at once. Each brand is a separate product from a separate manufacturer, and each one runs its own savings card, its own eligibility rules, and — for two of the four — its own patient assistance program. Treating them as interchangeable is the single most common way women overpay or get turned away at the pharmacy counter.

This page maps the real programs brand by brand, with the honest gaps included. If you already know which molecule you're on, our dedicated pages go deeper on that brand specifically: see Wegovy savings programs or the tirzepatide savings card for Zepbound and Mounjaro side by side.

Semaglutide coupon vs. tirzepatide coupon: they're not interchangeable

Because semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are frequently discussed together, it's easy to assume a coupon for one works for the other, or that the two molecules' savings programs are structured the same way. They aren't. Novo Nordisk and Eli Lilly run completely separate programs, with different dollar caps, different exclusion rules, and — critically — different patient assistance availability.

• Semaglutide (Novo Nordisk): Ozempic has a savings card and a real $0 patient assistance program; Wegovy has only the savings card, no PAP.
• Tirzepatide (Eli Lilly): Mounjaro has a savings card and Lilly Cares patient assistance; Zepbound has only the savings card, no equivalent free-medication program.
• A coupon for one brand cannot be applied to a prescription for the other brand, even within the same manufacturer — the programs check the specific drug name on your script.

The other trap: a Mounjaro or Ozempic savings card only applies when the prescription matches that drug's FDA-approved indication — type 2 diabetes. If your prescriber is writing an off-label weight-loss script on the diabetes brand because insurance won't cover Zepbound or Wegovy, don't assume the coupon follows automatically. Confirm with your pharmacist before counting on the discounted price.

How much can a GLP-1 savings card actually cut your bill?

For commercially insured patients whose plan covers the brand at all, the manufacturer savings card is the fastest, biggest cut available — bringing a monthly cost down to roughly $25, regardless of your plan's stated copay. Here's what each of the four cards actually offers.

• Wegovy Savings Card: $25/mo for commercially insured patients with Wegovy covered by their plan. No income limit — the qualifier is insurance type.
• Ozempic Savings Card: $25/mo for commercially insured type 2 diabetes patients, capped at $100/mo in total savings.
• Zepbound Savings Card: $25 per 1-3 month fill, up to $1,300/yr, for commercially insured patients whose plan covers Zepbound.
• Mounjaro Savings Card: $25 per fill, up to $1,950/yr, but only for a prescription written for type 2 diabetes — not off-label weight loss.

None of the four cards work with Medicare, Medicaid, TRICARE, VA, or any other government-funded insurance — that's a standard federal anti-kickback restriction on manufacturer coupons, not a brand-specific choice. If you're on any government plan, skip straight to the Medicare/Medicaid section further down instead of trying to enroll in a card you're not eligible for.

Is there a real patient assistance program for $0 GLP-1?

Yes, for two of the four brands. Ozempic's Patient Assistance Program (PAP) provides free medication to uninsured US patients with household income at or below 200% of the Federal Poverty Level. It's a genuine $0-a-month outcome for patients who qualify on both counts — uninsured, and under that income line.

Lilly Cares Foundation runs the equivalent program for Mounjaro: a free 12-month supply for uninsured, income-qualified patients (roughly 400% of the Federal Poverty Level) with a documented type 2 diabetes prescription. It's a materially higher income ceiling than Ozempic's PAP, which makes more patients eligible on the income test alone.

The honest gap: Wegovy and Zepbound currently have no equivalent free-medication program. If your prescription is for weight management on either of those brands and you don't qualify for a diabetes-indicated PAP on the sibling molecule, the next-cheapest routes are brand self-pay or compounded telehealth, covered in the next section.

No insurance, and don't qualify for a PAP — what actually works instead of a coupon

A meaningful share of readers land outside every program above: uninsured, income above the PAP threshold, or on a brand (Wegovy, Zepbound) that has no PAP at all. For this group, brand self-pay is the honest next-cheapest official route. NovoCare's direct self-pay program covers Wegovy and Ozempic starting around $149-$199/mo for lower doses and running up to $349-$499/mo at maintenance tiers. LillyDirect's self-pay vials cover Zepbound at $299-$449/mo, with a 45-day refill window that's worth a calendar reminder — miss it and the price jumps.

Below brand self-pay, compounded semaglutide or tirzepatide through a telehealth provider is currently the lowest-cost legitimate alternative, running from roughly $150/mo. It's pharmacy-mixed medication under a narrower legal pathway than it was a year ago, not an FDA-approved finished drug — a real distinction worth weighing, covered in full further down this page.

Does GoodRx actually work on GLP-1s?

It's worth a look, but temper expectations. GoodRx is known for cutting generic prices dramatically, and a lot of women assume the same applies here — it mostly doesn't, because all four of these brands are still under patent.

A recent pricing check found GoodRx running close to $900-$1,090/mo for Zepbound and Mounjaro — a modest discount off retail, not the deep cut GoodRx delivers on generics. That figure is unconfirmed and worth checking directly for your ZIP code before you rely on it; manufacturer pharmacy-benefit contracts limit how much a discount card can shave off a patent-protected brand.

The practical takeaway: if your insurance covers the brand at all, the manufacturer savings card will almost always beat GoodRx by a wide margin. GoodRx earns its place as a fallback to price-check, not a first move — and it can't be stacked with a savings card or insurance; you use one or the other.

Telehealth discount codes and intro pricing: the compounded route

If nothing above applies to you, compounded GLP-1s through telehealth providers are the realistic next-cheapest option. Fridays prices compounded semaglutide from about $150/mo with a 12-month prepay, or $249/mo month-to-month. Mochi Health uses flat-rate pricing — a separate membership fee plus a flat medication fee that doesn't increase as you titrate up. Henry Meds bundles the medication fee into one all-in monthly price with no separate membership.

Pricing structures differ enough between providers — prepay discounts, membership stacking, dose-based increases — that the cheapest advertised number isn't always the cheapest one you'll actually pay over a year. Compare your expected maintenance dose, not just the starter-dose price, before choosing.

Are there free GLP-1 samples? Here's what those ads are actually selling

By now you've seen the legitimate ways to get a GLP-1 for less — savings cards, real patient assistance, brand self-pay, compounded telehealth. That makes it easier to spot what "free GLP-1 samples" ads are actually offering, because it's rarely any of the above. Some are legitimate manufacturer "starter kits" — educational materials about beginning treatment, not free medication. Many more are third-party sites with no real program behind the claim at all.

The FDA has issued multiple warning letters over unauthorized sellers advertising discounted or free GLP-1 products outside the legitimate US supply chain, often alongside counterfeit product. The pattern is consistent enough to treat as a category, not isolated incidents.

• A site that offers free or heavily discounted GLP-1 medication with no prescription and no eligibility check is not a program — it's the profile of a scam.
• Legitimate savings programs (the cards and PAPs covered above) are always free to enroll in; anything asking for payment upfront just to "unlock" pricing is a red flag.
• Buy only through state-licensed pharmacies or vetted telehealth providers, and compare your product's packaging against the manufacturer's official images if anything looks off.

Does Medicare or Medicaid cover any of this?

None of the manufacturer savings cards work with Medicare or Medicaid — that exclusion is a fixed federal rule, not something that varies by brand or changes with renewal. Ozempic's PAP has also narrowed Medicare eligibility as of 2026, and Lilly Cares' Mounjaro program is built around uninsured patients specifically, not Medicare beneficiaries.

There is a separate CMS pilot that's been floated for some Medicare Part D beneficiaries — a 'Bridge'-style program targeting a roughly $50/mo copay for a GLP-1 with an approved cardiovascular or diabetes indication. That's a government program, not a manufacturer coupon, and terms were still firming up as of this writing; confirm directly with your Part D plan rather than assuming it applies to you.

Why the savings gap matters more in perimenopause

Weight gain in your forties and fifties often has a metabolic driver — shifting estrogen, worsening insulin resistance, fat redistribution toward the abdomen — that makes a GLP-1 a genuinely different proposition than a discretionary purchase for a lot of women. That reality doesn't change which program you qualify for, but it raises the stakes of getting the cheapest legitimate route right, since this is frequently a long-term prescription rather than a short course.

Annual math: card vs. self-pay vs. retail

• Savings card, insured (any brand, $25/mo or $25/fill): roughly $300/year out of pocket.
• Ozempic PAP, income-qualified: $0/year.
• Lilly Cares (Mounjaro, income-qualified): $0/year for a 12-month supply.
• NovoCare self-pay, starter tier (~$149-$199/mo): roughly $1,788-$2,388/year.
• NovoCare self-pay, maintenance tier (~$349-$499/mo): roughly $4,188-$5,988/year.
• LillyDirect self-pay, starter tier ($299/mo): roughly $3,588/year.
• LillyDirect self-pay, maintenance tier ($449/mo, on-time refills): roughly $5,388/year.
• GoodRx (~$900-$1,090/mo, unconfirmed): roughly $10,800-$13,080/year.
• Retail, no discount at all: can exceed $13,000/year depending on brand.

The gap that matters most: a qualifying PAP is worth the full retail price of the drug, and the savings card is worth thousands a year versus self-pay. Know which bracket you're actually in — insured-and-covered, PAP-eligible, self-pay, or none of those — before assuming any single number on this page is your answer.